Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB paid $48/share (93% premium) for Ra Pharma to bolt zilucoplan onto rozanolixizumab in gMG; Stifel modeled close to $2B peak sales and Jefferies over…
UCB frames the acquisition of Ra Pharmaceuticals and lead asset zilucoplan as joining forces to improve treatment options for people living with myasthenia…
CEO Jean-Christophe Tellier: 'This acquisition is a key part of this progress and an excellent strategic fit with UCB's strategy,' on completing the Ra…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
UCB acquired Ra Pharmaceuticals for $48/share in cash, a transaction valued at approximately $2.3 billion (EUR2.1 billion), announced October 10, 2019 and completed April 2, 2020. The lead asset, zilucoplan, is a once-daily subcutaneous, targeted peptide inhibitor of complement component 5 (C5), in pivotal Phase 3 (RAISE study) for generalized myasthenia gravis (gMG) at the time of the deal. The thesis fully played out: on October 17, 2023 the FDA approved zilucoplan as ZILBRYSQ for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive gMG -- the only once-daily, self-administered gMG-targeted therapy -- and UCB launched it commercially in the U.S.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Ra Pharmaceuticals, Inc. (this deal) | 2019 | $2.1B | — |
| UCB S.A. / Candid Therapeutics, Inc. | 2026 | $2.2B | — |
| UCB S.A. / Zogenix Inc. | 2022 | $1.9B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2019 deals · UCB S.A. deals · Immunology deals